Department of Nuclear Medicine, Klinikum rechts der Isar der Technischen Universität München, Munich, Germany.
Mol Imaging Biol. 2011 Oct;13(5):1011-9. doi: 10.1007/s11307-010-0383-0.
The aim of this study was to compare different analysis methods of 2-deoxy-2-[(18)F]fluoro-D-glucose positron emission tomography (FDG-PET) and magnetic resonance imaging (MRI) data for prediction of histopathological response (HPR) to neoadjuvant radiochemotherapy (RCTx) in patients with advanced rectal cancer.
Twenty-eight patients of a previously published clinical trial underwent serial FDG-PET/computed tomography scans at baseline, 14 days after initiation, and after completion of RCTx. In addition, MRI was performed at baseline and after the end of therapy. Response prediction was correlated with different image analysis algorithms comprising pure metabolic parameters taking into account the FDG uptake, volume-based parameters measuring the lesion volume in either MRI or PET data, and integrated parameters combining metabolic and volumetric information. The established two-dimensional (2D) regions of interest (ROI; diameter 1.5 cm) served as standard of reference. Changes between the parameters at the defined time points were calculated and analyzed for their potential to predict HPR to RCTx using receiver operating characteristic (ROC) analysis. Additionally, the interobserver reliability of fixed-size algorithms was analyzed.
Histopathology classified eight of 28 patients as non-responders and 20 patients as responders to RCTx. ROC analysis of the standard 2D ROI technique revealed areas under the curve (AUCs) of 0.64 and 0.71 for the early and late time points. Corresponding AUCs for three-dimensional (3D) volume of interest technique resulted in AUCs of 0.75 for both early and late time points, respectively. Volumetric parameters showed AUCs ranging from 0.52 to 0.57 (early time points) and 0.46 to 0.76 (later time points), respectively. Corresponding AUCs for the integrated parameters were ranging between 0.70 and 0.73 (early time points) and 0.66 and 0.76 (late time points). Analysis of intra-class correlation coefficients (ICC) for three different readers resulted in the best intra-class correlation values for the changes of 3D standard uptake value (SUV(3D)), for both early (ICC = 0.96) and late (ICC = 0.96) time points, respectively.
Our study emphasizes that 3D-based approaches for assessing SUV values consistently belonged to the group of parameters with the highest AUC values for prediction of HPR to neoadjuvant RCTx in patients with rectal cancer. MRI was not a good predictor for therapy response; hence, the MRI information derived from combined anatomic and metabolic parameters showed unsatisfying results too.
本研究旨在比较 2-脱氧-2-[(18)F]氟-D-葡萄糖正电子发射断层扫描(FDG-PET)和磁共振成像(MRI)数据的不同分析方法,以预测晚期直肠癌患者新辅助放化疗(RCTx)的组织病理学反应(HPR)。
28 例先前发表的临床试验患者在基线、RCTx 开始后 14 天和完成后进行了连续 FDG-PET/计算机断层扫描检查。此外,在基线和治疗结束后进行了 MRI 检查。通过不同的图像分析算法将反应预测与不同的图像分析算法相关联,这些算法包括考虑 FDG 摄取的纯代谢参数、测量 MRI 或 PET 数据中病变体积的基于体积的参数以及结合代谢和体积信息的综合参数。建立的二维(2D)感兴趣区域(ROI;直径 1.5 厘米)作为标准参考。在规定的时间点计算参数之间的变化,并使用接收者操作特征(ROC)分析来分析其预测 RCTx 中 HPR 的潜力。此外,还分析了固定大小算法的观察者间可靠性。
组织病理学将 28 例患者中的 8 例归类为 RCTx 无反应者,20 例为反应者。标准 2D ROI 技术的 ROC 分析显示,早期和晚期时间点的曲线下面积(AUC)分别为 0.64 和 0.71。三维(3D)体积感兴趣技术的相应 AUC 分别为 0.75。体积参数的 AUC 范围为 0.52 至 0.57(早期时间点)和 0.46 至 0.76(晚期时间点)。相应的综合参数 AUC 分别为 0.70 至 0.73(早期时间点)和 0.66 至 0.76(晚期时间点)。对 3 位不同读者的组内相关系数(ICC)进行分析,结果显示,3D 标准摄取值(SUV(3D))变化的组内相关值最佳,早期(ICC=0.96)和晚期(ICC=0.96)时间点分别为 0.96。
本研究强调,在评估 SUV 值时,基于 3D 的方法是预测直肠癌患者新辅助 RCTx 中 HPR 的最高 AUC 值参数组之一。MRI 不是治疗反应的良好预测指标;因此,来自解剖学和代谢参数组合的 MRI 信息也显示出令人不满意的结果。